



Improving access.
Transforming health.

August 8, 2025

The Honorable Mike Kelly
1707 Longworth HOB
Washington, DC 20510

The Honorable Chrissy Houlahan
1727 Longworth HOB
Washington, DC 20510

Dear Representatives Kelly and Houlahan,

On behalf of the Patient Access Network (PAN) Foundation and the patients and families we assist, I write in support of the Harley Jacobsen Clinical Trial Participant Income Exemption Act (H.R. 4184). PAN applauds you for reintroducing this important legislation that expands access to clinical trials and bolsters participation to ensure that treatments are safe and effective for all patient populations.

As a leading charitable foundation and healthcare advocacy organization, the PAN Foundation is dedicated to accelerating access to treatment for those who need it most and empowering patients on their healthcare journeys. We provide critical financial assistance for treatment costs, advocate for policy solutions that expand access to care, and deliver education on complex topics—all driven by our belief that everyone deserves access to affordable, equitable healthcare.

Financial barriers are a major obstacle to clinical trial participation. These burdens fall disproportionately on low-income individuals, who are historically underrepresented in medical research despite facing a higher disease burden. For example, studies have found that those with household incomes under \$50,000 are 32% less likely to enroll in trials than higher-income individuals. The Harley Jacobsen Clinical Trial Participant Income Exemption Act seeks to bridge this gap by reforming outdated tax policies that treat clinical trial compensation as taxable income. By removing this financial disincentive, the legislation will strengthen national clinical trial recruitment and retention efforts and help ensure that new treatments and therapies reflect the populations most impacted by the disease being studied. Importantly, the bill recognizes how current tax reporting rules can be a serious deterrent for individuals and families who rely on programs like SNAP and WIC. Passing your legislation is necessary to reap the results of our nation's investment in medical innovation and ensure life-changing therapies are effective for all patients that need them.

The PAN Foundation appreciates your leadership in seeking solutions to increase participation in clinical trials and improve health outcomes for all Americans. We look forward to working with you to educate on the importance of passing your legislation. If you would like further information or have questions, please contact Amy Niles, Chief Mission Officer at aniles@panfoundation.org.

Sincerely,

A handwritten signature in black ink that reads "Kevin L. Hagan". The signature is fluid and cursive, with the first name "Kevin" being the most prominent.

Kevin L. Hagan
President and Chief Executive Officer